

Fei Luo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1040270/publications.pdf>

Version: 2024-02-01

23
papers

683
citations

687363

13
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1046
citing authors

#	ARTICLE	IF	CITATIONS
1	TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. <i>Hepatology Communications</i> , 2022, 6, 448-460.	4.3	51
2	Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 879-899.	4.5	36
3	Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111803.	5.6	16
4	Missense variant in insulin receptor (Y1355H) segregates in family with fatty liver disease. <i>Molecular Metabolism</i> , 2021, 53, 101299.	6.5	1
5	Metabolomics reveals metabolite changes of patients with pulmonary arterial hypertension in China. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2484-2496.	3.6	47
6	Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. <i>Cardiovascular Diabetology</i> , 2019, 18, 54.	6.8	116
7	Multivessel Coronary Revascularization Strategies in Patients with Chronic Kidney Disease: A Meta-Analysis. <i>CardioRenal Medicine</i> , 2019, 9, 145-159.	1.9	12
8	GDF-15 levels and atherosclerosis. <i>International Journal of Cardiology</i> , 2018, 257, 36.	1.7	7
9	Oligonucleotides targeting ANGPTL3. <i>International Journal of Cardiology</i> , 2018, 256, 8.	1.7	2
10	Therapeutic antagonism of ANGPTL4. <i>International Journal of Cardiology</i> , 2018, 256, 1.	1.7	3
11	<scp>TPPU</scp> enhanced exercise-induced epoxyeicosatrienoic acid concentrations to exert cardioprotection in mice after myocardial infarction. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 1489-1500.	3.6	26
12	Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer. <i>Cancer Medicine</i> , 2018, 7, 6158-6169.	2.8	20
13	ANGPTL3 possibly promotes cardiac angiogenesis through improving proangiogenic ability of endothelial progenitor cells after myocardial infarction. <i>Lipids in Health and Disease</i> , 2018, 17, 184.	3.0	12
14	Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet. <i>Scientific Reports</i> , 2017, 7, 2169.	3.3	29
15	Polypill-Based Therapy: A Promising Therapeutic Strategy. <i>Heart Lung and Circulation</i> , 2017, 26, 423-424.	0.4	0
16	Concerns on the Genetic Therapeutic Antagonism of ANGPTL3. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2099.	2.8	4
17	Estrogen lowers triglyceride via regulating hepatic APOA5 expression. <i>Lipids in Health and Disease</i> , 2017, 16, 72.	3.0	16
18	Does PEDF improve atherosclerotic plaque stability by inhibiting VSMCs' apoptosis?. <i>International Journal of Cardiology</i> , 2017, 242, 11.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Regulatory non-coding <scp>RNA</scp>s in acute myocardial infarction. Journal of Cellular and Molecular Medicine, 2017, 21, 1013-1023.	3.6	79
20	17 β -estradiol lowers triglycerides in adipocytes via estrogen receptor α and it may be attenuated by inflammation. Lipids in Health and Disease, 2017, 16, 182.	3.0	15
21	Hypertriglyceridemia and atherosclerosis. Lipids in Health and Disease, 2017, 16, 233.	3.0	163
22	Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism. Lipids in Health and Disease, 2016, 15, 109.	3.0	19
23	Fibroblast growth factor 21 potentially inhibits microRNA-33 expression to affect macrophage actions. Lipids in Health and Disease, 2016, 15, 208.	3.0	9